Combination therapy for advanced cancers that have stopped responding to treatment
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced cancer that has spread or come back, and standard treatments are no longer working or are not an option.
- You have at least one tumor that is 1 cm or larger on a scan.
- Your blood test shows a low lymphocyte count (a type of white blood cell).
- You are generally able to care for yourself (can be up to bedridden, but not completely) and expected to live at least 3 months.
- You do not have serious heart, kidney, or liver problems, and no active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
Hear when a new Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.